Ardent Health 2026 UBS Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Well, next up in this room is Ardent Health. We're very pleased to have them participating in the conference this year. Dave and team, I guess just introductory comment. We're what, 10, 11, almost 11 months into the year at this point. How would you describe how the year's gone? I know you've had some transitions, but what have been the positives, what have been the challenges, and maybe level set us a little bit on that.
I'll get us started here. First of all, I'm really pleased with the team's work around expense control. The IMPACT program and the work that's been underway to sharpen what is the first of three pillars of our growth strategy, and that's operational excellence. They've been very focused at growing stronger. Secondarily, tied within there, our second pillar there is around organic growth. The team, we've stood up a team called Products and Services that is very focused on what we call Capacity IQ and strengthening our selection and service line choices so that we're providing the right service to the customer and the right business model for ourselves. Those are probably the areas I feel strongest about what our team's been doing that we can be bold about. Third, in our growth strategy, the M&A activity.
While teams have been very focused on the discipline activity there, no tangible items to produce as of yet, but very encouraging where we are, very positioned for action. But overall, really thankful for what the team's doing, very centered on impact.
Okay. Yeah, when we think about just how the year has played out, AJ, obviously it hasn't been exactly to plan, right?
I think if you look across the hospital space, volumes have been softer at the bottom of the funnel than anybody expected. So surgical demand has been weaker than anybody expected coming into the year. But to Dave's point, we've actually been able to raise the midpoint of our guidance off of our Q3 call, off of the, I'd say, controlling the controllables, really focused on delivering and executing, no matter what the volume demand backdrop is. Now, the good news is, at the top of our funnel, we think demand has been continued to be very strong.
It's been surgical demand specifically where we've seen some weakness and real focus on, again, going back to controlling the controllables and working on all the things we can do to remove friction in the process so that we set ourselves up for converting as that top of the funnel demand into surgical volume.
Right. Okay. A number of things I want to drill down operationally, but I guess given the events of the last week, maybe I'll take a step back and just ask you about those and get that out of the way. Obviously, we had the midterm elections, Democrats taking over the House and Senate. How does that changing political landscape impact the company's strategy at all and how you're thinking about the future?
For now, unchanged. Right. Unchanged.
We are bullish about controlling the controllables. We're going to stay focused and steadfast, and if tailwinds arrive, we're going to take them as tailwinds.
Okay. But for now, unchanged.
Okay. I know the incoming Speaker of the House, Hakeem, likely Speaker of the House, I guess I should say, Hakeem Jeffries said he wants to look at the Trump Medicaid cuts, quote unquote, and potentially restore the ACA subsidies. Any view from what you're hearing from the trade association or otherwise about whether you think there will be action quickly on that, or is it going to be another one of these Congress only acts when they're absolutely have their back against the wall, so it will be later next year or before we see something?
Any thoughts? Well, if there's anything the last few years have proven to me is that predicting what's going to happen from a policy perspective is not something I'm particularly good at.
I would say, going back to Dave's comments, we're highly focused on executing in the environment we're in today. Having said all of that, we're clearly supportive of anything that expands coverage or provides enhanced access to the most vulnerable populations. We think it's good policy to provide more access and to ensure that the most vulnerable populations have access to care, and anything that provides and supports those populations, we're supportive of.
Okay. No, that's fair. So one of the things that you guys have been focused on in recent months is this IMPACT program. Maybe describe that for our investors, and how do you see that impacting growth and margin, frankly, over the next few years?
Mm-hmm. IMPACT has been an imperative initiative for us. The first portion of what IMPACT really is the improving margin portion. Inside of improving margin, we are a scaling company, not a scaled company. In scaling, it gives us the opportunity to really reinvent and follow some of the protocols that have been set before us around taking a single hospital to a campus type of structure, looking at, as we do that, how does that impact FTEs and mid-level management, and how do we coordinate and organize to reduce SWB? On our Q3 earnings, we represented a 4% improvement in SWB. That work is working. It's durable and sustainable. As parts of IMPACT as well, supply chain, a key focus, ensuring revenue cycle excellence and care transformation all fit within there.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
4 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
